Of remark, these beneficial effects on hepatic fibrosis were accompanied in both AAVIGF-I and SVIGF-I groups by a general normalization of hepatocellular function, as estimated by serum bilirubin (non-significantly different between healthy and IGF-I-treated animals) and albumin levels (which were similar in healthy and IGF-I-treated animals) observed at 8 weeks post-therapy (Fig 7). The gene discussed is ALB; the disease is Hepatic fibrosis.